Literature DB >> 20842491

Treatment of thyroid eye disease.

Margaret E Phillips1, Mehrak M Marzban, Sajeev S Kathuria.   

Abstract

OPINION STATEMENT: Thyroid eye disease (TED) is an autoimmune disease characterized by varying degrees of proptosis, congestion and inflammation of the extraocular tissues, and eyelid retraction. It is usually seen in the setting of Graves' disease, but the severity of TED does not necessarily correlate with the level of systemic disease in a given patient. It is very important, nonetheless, to try to achieve a euthyroid state to minimize the chances of exacerbation of TED. Treatment of TED is based on the signs and symptoms displayed by the patient; there is no "one size fits all" approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking, because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations. Once there is significant improvement in the acute inflammation, it is useful to treat patients who have residual inflammation with external beam radiation in order to be able to wean the patient off steroids and avoid their well-known complications.If there is significant corneal exposure due to lid retraction, and the lid position has been stable for at least 6 months, eyelid surgery can be considered. If exposure is minimal, this may consist of a lateral tarsorrhaphy. For larger amounts of exposure, recession of the levator muscle, Müller's muscle, or both can be performed. Those patients who have stable diplopia for at least 6 months are candidates for strabismus surgery. Patients who progress to severe proptosis or compressive optic neuropathy may need orbital decompression surgery. Generally, if more than one type of surgical procedure is necessary, orbital decompression is performed first, followed by strabismus surgery; eyelid surgery is performed last.

Entities:  

Year:  2010        PMID: 20842491     DOI: 10.1007/s11940-009-0054-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  8 in total

Review 1.  Epidemiology and prevention of Graves' ophthalmopathy.

Authors:  Wilmar M Wiersinga; Luigi Bartalena
Journal:  Thyroid       Date:  2002-10       Impact factor: 6.568

2.  Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype.

Authors:  N Manji; J D Carr-Smith; K Boelaert; A Allahabadia; M Armitage; V K Chatterjee; J H Lazarus; S H S Pearce; B Vaidya; S C Gough; J A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

Review 3.  Evaluation and management of Graves' orbitopathy.

Authors:  H B Harold Lee; I Rand Rodgers; John J Woog
Journal:  Otolaryngol Clin North Am       Date:  2006-10       Impact factor: 3.346

Review 4.  Current insights into the pathogenesis of Graves' orbitopathy.

Authors:  A K Eckstein; K T M Johnson; M Thanos; J Esser; M Ludgate
Journal:  Horm Metab Res       Date:  2009-06       Impact factor: 2.936

5.  Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.

Authors:  Dinesh Khanna; Kelvin K L Chong; Nikoo F Afifiyan; Catherine J Hwang; Diana K Lee; Helene Chokron Garneau; Robert A Goldberg; Christine H Darwin; Terry J Smith; Raymond S Douglas
Journal:  Ophthalmology       Date:  2009-10-08       Impact factor: 12.079

6.  Clinical features of Graves' ophthalmopathy in an incidence cohort.

Authors:  G B Bartley; V Fatourechi; E F Kadrmas; S J Jacobsen; D M Ilstrup; J A Garrity; C A Gorman
Journal:  Am J Ophthalmol       Date:  1996-03       Impact factor: 5.258

7.  The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.

Authors:  G B Bartley
Journal:  Trans Am Ophthalmol Soc       Date:  1994

Review 8.  Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.

Authors:  Elizabeth A Bradley; Emily W Gower; David J Bradley; Dale R Meyer; Kenneth V Cahill; Philip L Custer; David E Holck; John J Woog
Journal:  Ophthalmology       Date:  2008-02       Impact factor: 12.079

  8 in total
  4 in total

1.  Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

Authors:  David B Granet; Nickisa Hodgson; Kyle J Godfrey; Ricardo Ventura; Don O Kikkawa; Leah Levi; Michael Kinori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-10       Impact factor: 3.117

2.  Treatment options for thyroid eye disease.

Authors:  Angelique J Pillar; D Chimene Richa
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

3.  Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT.

Authors:  Chiara Del Noce; Matilde Roda; Lorenzo Ferro Desideri; Carlo E Traverso; Aldo Vagge
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-01       Impact factor: 3.117

4.  Old Bottle, New Wine: Diplopia Sans Proptosis as the Sole Presentation of Thyroid Orbitopathy.

Authors:  Divyani Garg; Ankit Gupta; Rajinder K Dhamija
Journal:  Cureus       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.